Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Benefits in patient comfort, efficiency, and sustainability can come from reducing positron emission tomography (PET) scan's acquisition duration. This study assesses the clinical adequacy of restoring fast-acquisition F-fluorodeoxyglucose ([F]FDG) PET to its standard-of-care image quality through deep-learning-based (DL) methods. Fast and standard whole-body [F]FDG PET acquisitions of 117 oncological patients were included in the training and testing of three convolutional neural networks. The best-performing network during training was chosen for clinical evaluation on the test set (N = 25). Visual assessment and lesion detectability of the fast acquisitions, of 20 and 30 seconds per axial field of view (s/AFOV), with and without DL-based denoising, and of the local standard of care, of 70 s/AFOV, were performed by three experienced nuclear medicine physicians. Quantification was conducted globally (voxel-wise), in healthy organs and the reported lesions. Optimised Gaussian and non-local means filters served as benchmarks. Visual assessment revealed 20 and 30 s/AFOV with DL-based denoising to have similar image quality to the standard of care. Average lesion-based sensitivity and positive predictive value were 74% and 72%, respectively, for 20 s/AFOV + DL and 72% and 80% for 30 s/AFOV + DL. DL-based denoising displayed the highest voxel-wise agreement with the standard-of-care (p < 0.001). Liver and lungs in the DL-denoised images exhibited a higher signal-to-noise ratio than the standard of care. The median absolute maximum standardised uptake value deviation in the lesions was as low as 0.39 for 20 s/AFOV + DL and 0.30 for 30 s/AFOV + DL. The proposed DL-based method proved to be suitable for the restoration of fast-acquisition whole-body [F]FDG PET, having resulted in images similar to the standard-of-care acquisitions. DL-based denoising outperformed standard benchmark methods.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10278-025-01638-9DOI Listing

Publication Analysis

Top Keywords

[f]fdg pet
12
dl-based denoising
12
image quality
8
visual assessment
8
s/afov dl-based
8
standard care
8
ai-based solution
4
denoising
4
solution denoising
4
denoising fast-acquisition
4

Similar Publications

Objectives: Lymph node metastasis (LNM) is an important factor affecting the stage and prognosis of patients with lung adenocarcinoma. The purpose of this study is to explore the predictive value of the stacking ensemble learning model based on F-FDG PET/CT radiomic features and clinical risk factors for LNM in lung adenocarcinoma, and elucidate the biological basis of predictive features through pathological analysis.

Methods: Ninety patients diagnosed with lung adenocarcinoma who underwent PET/CT were retrospectively analyzed and randomly divided into the training and testing sets in a 7:3 ratio.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive type of non-Hodgkin lymphoma. Accurate evaluation of treatment response is essential for effective management. This case report discusses the potential role of ⁶⁸Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in comparison to F-fluorodeoxyglucose PET/CT for assessing treatment response in a patient with DLBCL.

View Article and Find Full Text PDF

Metastatic renal osteosarcoma is a rare entity. We report a case of a 52-year-old male postright nephrectomy status presented to us with metastatic renal osteosarcoma. 18-fluorine- fluorodeoxyglucose (F-FDG) avid lesions were seen in the right renal bed with extension to adjacent hepatic parenchyma.

View Article and Find Full Text PDF

Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans cell histiocytosis with multiple organ involvement. Being a rare disease with variable clinical manifestations, it is often difficult to diagnose. F-2-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays a vital role in assessing disease extent and severity, diagnosis, treatment response and is a potential biomarker for BRAF mutation.

View Article and Find Full Text PDF

Lung cancer is the leading cause of cancer and cancer-related deaths, and India ranks the fourth highest country. Lung cancer is a highly aggressive malignancy with a tendency for rapid progression, making early detection and prompt treatment essential for improving patient outcomes. Lung cancer can spread locally into surrounding tissue as well as travel through lymphatics to other parts of the body, most often to bone, brain, liver, and adrenal glands.

View Article and Find Full Text PDF